Acutend, Inc. appears to be a small medical/consumer medical‑device company that developed an FDA‑cleared neurostimulation product; corporate records place an entity named Acutend, Inc. as incorporated in New York in February 2017 and prior references connect the name to a device venture in Silicon Valley led earlier by entrepreneurs in the medical‑device space[2][5][1].
High‑Level Overview
- Concise summary: Acutend, Inc. is reported as a consumer medical‑device company that developed a Class I, FDA‑cleared neurostimulation device focused on non‑invasive therapies; public company directory and startup listings identify the company in Silicon Valley, while incorporation records show an Acutend, Inc. filing in New York in 2017[2][5].
- For a portfolio/company framing: Product — a Class I, FDA‑cleared neurostimulation medical device[2]. Who it serves — consumers/patients seeking non‑invasive neurostimulation therapies (medical/consumer markets)[2]. Problem it solves — provides a non‑invasive therapeutic option using neurostimulation technology (marketing and biographical notes claim it was positioned as clinically proven and FDA‑cleared)[1][2]. Growth momentum — public sources are limited; no comprehensive funding, revenue, or growth data found in the results provided, so momentum cannot be reliably assessed from these sources[2][5].
Origin Story
- Founding & background: Public profiles link the Acutend name to entrepreneurs in medical devices, and a biographical item indicates Patrick Suel founded Acutend to develop an FDA‑cleared non‑invasive device (his CV lists founding Acutend in the mid‑2000s through 2010) though that reference may describe an earlier incarnation or project using the Acutend name rather than the New York‑incorporated 2017 entity[1][5].
- How idea emerged & early traction: Gust and other startup directories describe Acutend as having developed a Class I FDA‑cleared neuro‑stimulation device, which suggests early regulatory traction (FDA clearance) and product development success[2]. Beyond FDA clearance and directory listings there are no detailed public accounts of seed customers, clinical trial results, venture financing, or commercialization milestones in the search results provided[2][1].
Core Differentiators
- Product differentiator: FDA Class I clearance for a consumer neurostimulation device positions it as a regulated, non‑invasive option within its category[2].
- Clinical/regulatory evidence: Biographical notes assert the device was “clinically proven” and FDA‑cleared, which would be a meaningful differentiator if corroborated by clinical publications or FDA documents (none located in the provided results)[1][2].
- Geographic/organizational: Listed as Silicon Valley–based in startup directories, but incorporation filing shows a New York entity (Feb 21, 2017), indicating either relocation, separate entities, or multiple filings[2][5].
- Unknowns: No accessible information on pricing, developer experience, platform ecosystem, customer base, or a track record of commercial scale in the available search results.
Role in the Broader Tech / Health Landscape
- Trend alignment: Acutend fits within the trend toward consumer neurotechnology and non‑invasive neuromodulation devices for wellness and medical indications, a growing area in digital health and medical devices[2].
- Timing and market forces: Rising consumer interest in at‑home neurostimulation, regulatory pathways for low‑risk devices, and investment into digital therapeutics favor companies with FDA‑cleared, user‑friendly devices; specifics for Acutend’s market timing or competitive positioning are not detailed in the sources[2].
- Influence: Available sources do not document a broad ecosystem impact (e.g., partnerships, large‑scale deployments, or venture rounds), so its influence appears limited or not publicly reported based on these results[2][5].
Quick Take & Future Outlook
- What’s next / likely paths: With an FDA‑cleared consumer neurostimulation device, logical next steps would be commercialization scaling (distribution, direct‑to‑consumer or clinical channels), clinical evidence publication to support claims, and potential fundraising or partnerships to grow market reach—none of which are documented in the provided results[2][1].
- Risks & uncertainties: Publicly available information is sparse and partly inconsistent (Silicon Valley listings vs. New York incorporation and historical biographical mentions), so uncertainties remain about current operational status, leadership, funding, and market traction[2][5][1].
- Final note: The sources show Acutend as a small device developer with FDA clearance listed, but there is insufficient public documentation in the provided results to produce a detailed financial or operational profile; verifying current status would require direct company materials (website, leadership bios, FDA 510(k) or registration records, press releases) or corporate filings beyond the directory and single incorporation record cited here[2][5][1].
If you want, I can: (a) search for FDA registration/510(k) records and clinical publications for Acutend’s device, (b) look up leadership profiles and press releases to clarify founding and timeline, or (c) attempt deeper corporate records searches (state filings, Crunchbase, LinkedIn). Which would you prefer?
